Fig. 3: Progression-free survival (PFS) and overall survival (OS) of NSCLC patients treated with gemcitabine. | Cell Death Discovery

Fig. 3: Progression-free survival (PFS) and overall survival (OS) of NSCLC patients treated with gemcitabine.

From: Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer

Fig. 3

A The PFS graph indicates a trend towards longer progression-free survival in patients with TP53 hotspot mutations (n = 3) compared to other mutation groups. B The overall survival after receiving gemcitabine appears to be longer in the TP53 hotspot mutation group, although the difference is not statistically significant (P value: 0.374) when compared to the TP53 non-hotspot mutation group (n = 18) and the TP53 wild-type group (n = 15).

Back to article page